
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.
It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.
It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.